168 related articles for article (PubMed ID: 19092374)
1. Clinical implications of diffuse hepatic uptake observed in postablative and post-therapeutic I-131 scans.
Omür O; Akgün A; Ozcan Z; Sen C; OzkiIiç H
Clin Nucl Med; 2009 Jan; 34(1):11-4. PubMed ID: 19092374
[TBL] [Abstract][Full Text] [Related]
2. The comparison of (131)I whole-body scans on the third and tenth day after (131)I therapy in patients with well-differentiated thyroid cancer: preliminary report.
Lee JW; Lee SM; Koh GP; Lee DH
Ann Nucl Med; 2011 Jul; 25(6):439-46. PubMed ID: 21476057
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the surgical completeness after total thyroidectomy for differentiated thyroid carcinoma.
Salvatori M; Raffaelli M; Castaldi P; Treglia G; Rufini V; Perotti G; Lombardi CP; Rubello D; Ardito G; Bellantone R
Eur J Surg Oncol; 2007 Jun; 33(5):648-54. PubMed ID: 17433606
[TBL] [Abstract][Full Text] [Related]
4. Prediction of treatment response to ¹³¹I therapy by diffuse hepatic uptake intensity on post-therapy whole-body scan in patients with distant metastases of differentiated thyroid cancer.
Jun S; Lee JJ; Park SH; Kim TY; Kim WB; Shong YK; Ryu JS
Ann Nucl Med; 2015 Aug; 29(7):603-12. PubMed ID: 25980591
[TBL] [Abstract][Full Text] [Related]
5. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of diffuse hepatic uptake on post-therapeutic early and delayed (131)I scan in differentiated thyroid cancer: a preliminary report.
Lee JW; Lee SM; Choi J
Ann Nucl Med; 2015 Feb; 29(2):190-7. PubMed ID: 25413273
[TBL] [Abstract][Full Text] [Related]
7. Undetectable thyroglobulin in patients with differentiated thyroid carcinoma and residual radioiodine uptake on a postablation whole-body scan.
Giovanella L; Suriano S; Ceriani L; Verburg FA
Clin Nucl Med; 2011 Feb; 36(2):109-12. PubMed ID: 21220971
[TBL] [Abstract][Full Text] [Related]
8. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
[TBL] [Abstract][Full Text] [Related]
9. Association between residual thyroid carcinoma and diffuse hepatic uptake of 131I following radioiodine ablation in postoperative total thyroidectomy patients.
Tatar FA; Morita E; Ituarte PH; Cavalieri RR; Duh QY; Price DC; Siperstein AE; Clark OH
World J Surg; 2001 Jun; 25(6):718-22. PubMed ID: 11376405
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of hepatic visualization on iodine-131 whole-body scan in patients with thyroid carcinoma.
Chung JK; Lee YJ; Jeong JM; Lee DS; Lee MC; Cho BY; Koh CS
J Nucl Med; 1997 Aug; 38(8):1191-5. PubMed ID: 9255147
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of persistent radioiodine uptake in the neck shown by diagnostic whole body scan in patients with differentiated thyroid carcinoma after initial surgery and remnant ablation.
Kim EY; Kim WG; Kim WB; Kim TY; Ryu JS; Gong G; Yoon JH; Hong SJ; Lee JH; Baek JH; Shong YK
Clin Endocrinol (Oxf); 2010 Aug; 73(2):257-63. PubMed ID: 20105187
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
[TBL] [Abstract][Full Text] [Related]
13. The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer.
Van Nostrand D; Aiken M; Atkins F; Moreau S; Garcia C; Acio E; Burman K; Wartofsky L
Thyroid; 2009 Aug; 19(8):849-55. PubMed ID: 19281428
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma.
Tepmongkol S; Keelawat S; Honsawek S; Ruangvejvorachai P
Thyroid; 2008 Jul; 18(7):697-704. PubMed ID: 18630997
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of diffuse hepatic visualization and thyroid bed uptake on post-ablative iodine-131 whole body scan in differentiated thyroid cancer.
Kim K; Kim SJ; Kim IJ; Kim YK; Kim BS; Pak K
Onkologie; 2012; 35(3):82-6. PubMed ID: 22414970
[TBL] [Abstract][Full Text] [Related]
16. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma.
Cherk MH; Kalff V; Yap KS; Bailey M; Topliss D; Kelly MJ
Clin Endocrinol (Oxf); 2008 Dec; 69(6):957-62. PubMed ID: 18419785
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic implications of diffuse hepatic uptake following I-131 therapy for differentiated thyroid cancer.
Ferris HA; Williams G; Parker JA; Garber JR
Endocr Pract; 2013; 19(2):263-7. PubMed ID: 23529347
[TBL] [Abstract][Full Text] [Related]
18. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients.
Schlumberger M; Lacroix L; Russo D; Filetti S; Bidart JM
Nat Clin Pract Endocrinol Metab; 2007 Mar; 3(3):260-9. PubMed ID: 17315034
[TBL] [Abstract][Full Text] [Related]
19. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
Taïeb D; Sebag F; Cherenko M; Baumstarck-Barrau K; Fortanier C; Farman-Ara B; De Micco C; Vaillant J; Thomas S; Conte-Devolx B; Loundou A; Auquier P; Henry JF; Mundler O
Clin Endocrinol (Oxf); 2009 Jul; 71(1):115-23. PubMed ID: 18803678
[TBL] [Abstract][Full Text] [Related]
20. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.
Grewal RK; Larson SM; Pentlow CE; Pentlow KS; Gonen M; Qualey R; Natbony L; Tuttle RM
J Nucl Med; 2009 Oct; 50(10):1605-10. PubMed ID: 19759114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]